The oral PLK1 inhibitor onvansertib received FDA orphan drug designation in CMML.
Related to this article
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Advertisement
Advertisement
Trending on OncLive
1
Teclistamab Monotherapy Wins EU Approval for R/R Myeloma After at Least 1 Prior Therapy
2
OncLive Weekly News Quiz (10/23/2026): Did You Miss Crucial Rectal, Bladder, and Kidney Cancer Updates?
3
Perioperative Nivolumab Plus Neoadjuvant Chemotherapy Misses Co-Primary End Points in Muscle-Invasive Bladder Cancer
4
Adding UV1 Vaccine to Olaparib/Durvalumab Maintenance Misses PFS End Point in BRCA-Wild Type Recurrent Ovarian Cancer
5